Your browser doesn't support javascript.
loading
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume, Patrick A; Biner, Reta Fischer; Downey, Damian G; Brown, Cynthia; Jain, Manu; Fischer, Rainald; De Boeck, Kris; Sawicki, Gregory S; Chang, Philip; Paz-Diaz, Hildegarde; Rubin, Jaime L; Yang, Yoojung; Hu, Xingdi; Pasta, David J; Millar, Stefanie J; Campbell, Daniel; Wang, Xin; Ahluwalia, Neil; Owen, Caroline A; Wainwright, Claire E.
Afiliación
  • Flume PA; MUSC Health Cystic Fibrosis Center, Medical University of South Carolina, Charleston, SC, USA. Electronic address: flumepa@musc.edu.
  • Biner RF; Quartier Bleu, Lindenhof Hospital, Bern, Switzerland.
  • Downey DG; Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK.
  • Brown C; Department of Pulmonary and Critical Care Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Jain M; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Fischer R; Pneumologische Praxis München-Pasing, Munich, Germany.
  • De Boeck K; Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium.
  • Sawicki GS; Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Chang P; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Paz-Diaz H; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Rubin JL; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Yang Y; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Hu X; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Pasta DJ; ICON Clinical Research Inc, North Wales, PA, USA.
  • Millar SJ; ICON Clinical Research Inc, North Wales, PA, USA.
  • Campbell D; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Wang X; Vertex Pharmaceuticals Incorporated, Boston, MA, USA; US Food and Drug Administration, Silver Spring, MD, USA.
  • Ahluwalia N; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Owen CA; Vertex Pharmaceuticals Incorporated, Boston, MA, USA.
  • Wainwright CE; Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia.
Lancet Respir Med ; 9(7): 733-746, 2021 07.
Article en En | MEDLINE | ID: mdl-33581080
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinolonas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística / Benzodioxoles / Aminofenoles / Indoles / Mutación Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male País/Región como asunto: America do norte / Asia / Europa / Oceania Idioma: En Revista: Lancet Respir Med Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinolonas / Regulador de Conductancia de Transmembrana de Fibrosis Quística / Fibrosis Quística / Benzodioxoles / Aminofenoles / Indoles / Mutación Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male País/Región como asunto: America do norte / Asia / Europa / Oceania Idioma: En Revista: Lancet Respir Med Año: 2021 Tipo del documento: Article